-
Mashup Score: 0Momelotinib Bests Danazol in Symptomatic, Anemic Myelofibrosis - 2 year(s) ago
Momelotinib proved superior to danazol in patients with symptomatic, anemic myelofibrosis in a phase 3 study.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital and Paris Diderot University, Paris, France, discusses a retrospective analysis of the SIMPLIFY-1 (NCT01969838)…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Momelotinib vs. #Ruxolitinib in #Myelofibrosis patients with thrombocytopenia. Check out the findings of the SIMPLIFY trials with @jjkiladjian from @Univ_Paris: https://t.co/hNaJNn5inb #ASH20 @ASH_hematology #HemOnc #MPNsm #CTSM #TrialUpdate #WorldCancerDay #IAmAndIWill
-
-
Mashup Score: 1Analysis of long-term exposure to momelotinib in the Phase III SIMPLFY myelofibrosis trials - 3 year(s) ago
Srdan Verstovsek, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, shares long-term outcome data from the Phase…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Srdan Verstovsek of @MDAndersonNews presented data on the long-term exposure to #Momelotinib in JAKi-naïve & previously JAKi-treated patients with #Myelofibrosis Find his interview w/ @VJHemOnc here: https://t.co/HctdwecHXT #ASH20 @ASH_hematology @OncoAlert #HemOnc #MPNsm #CTsm https://t.co/ANfOA4eYtw
-
-
Mashup Score: 0Update on momelotinib for myelofibrosis - 4 year(s) ago
Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, updates us on the clinical use of momelotinib, a…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📢PRESENTING NOW: @AYACOUB7 is giving an update on #Momelotinib for myelofibrosis 👂Listen to our interview with him @VJHemOnc: https://t.co/cgbNeveivk @UTHealthSAMDA @LeukemiaMDA #TxMPN2020 @OncoAlert #MPN #MPNsm #Leusm https://t.co/p9nWvtetTr
-
#Momelotinib proved superior to danazol for key outcomes in a phase 3 trial of patients with symptomatic and anemic #myelofibrosis. Presented at the @EHA_Hematology conference #EHA2022. https://t.co/HjcSzqUaON